pediatric malignant solid tumors christosova,brankov
TRANSCRIPT
![Page 1: Pediatric malignant solid tumors christosova,brankov](https://reader035.vdocuments.mx/reader035/viewer/2022062312/556b09abd8b42ae47d8b4936/html5/thumbnails/1.jpg)
PEDIATRIC MALIGNANT SOLIDTUMORS
Iskra Christosova,
Ognyan Brankov
Pediatric Oncohaematology
Pediatric Surgery
Sofia BULGARIA
![Page 2: Pediatric malignant solid tumors christosova,brankov](https://reader035.vdocuments.mx/reader035/viewer/2022062312/556b09abd8b42ae47d8b4936/html5/thumbnails/2.jpg)
Pediatric Cancer
2 nd leading cause of death in children 1/350 children diagnosed annually or the incidence per year would be 15-16
cases / 100 000 children per year/ 11 000 new cases in children under 20 years
of age each year in the whole world. Considered in the past as hopeless diseases
now 70% of children with cancer can be cured definitively
![Page 3: Pediatric malignant solid tumors christosova,brankov](https://reader035.vdocuments.mx/reader035/viewer/2022062312/556b09abd8b42ae47d8b4936/html5/thumbnails/3.jpg)
CancerogenesisI. Exogenous Factors
Radiation Exposure. Other Factors of the Surrounding. Enviroment -
Chemical Cancerogens. Oncogenic Viruses.
![Page 4: Pediatric malignant solid tumors christosova,brankov](https://reader035.vdocuments.mx/reader035/viewer/2022062312/556b09abd8b42ae47d8b4936/html5/thumbnails/4.jpg)
II. Endogenous Factors
Familial and Genetic Factor Cancer Malformation Syndromes Multiple Primary Tumors Second Malignant Neoplasms
![Page 5: Pediatric malignant solid tumors christosova,brankov](https://reader035.vdocuments.mx/reader035/viewer/2022062312/556b09abd8b42ae47d8b4936/html5/thumbnails/5.jpg)
Charactreristic Features ofChildhood Cancer
Child’s Organism is with forming Immune System and with Rapid Growth.
Different Histological Types from those of Adults.
Different Localizations from those of Adults. Higher Sensitiveness to Chemotherapy than
Adults.
![Page 6: Pediatric malignant solid tumors christosova,brankov](https://reader035.vdocuments.mx/reader035/viewer/2022062312/556b09abd8b42ae47d8b4936/html5/thumbnails/6.jpg)
Clasification of Pediatric Malignancies
Systemic Neoplasms (Leukaemias and Lymphomas) : Solid Tumors = 1:1.
![Page 7: Pediatric malignant solid tumors christosova,brankov](https://reader035.vdocuments.mx/reader035/viewer/2022062312/556b09abd8b42ae47d8b4936/html5/thumbnails/7.jpg)
Systemic Neoplasms - 50%
Leukaemias - 1/3 of Pediatric neoplasms - 35% Lymphomas (NHL 55% and Hodgkin’s Disease
45%) - 15%
![Page 8: Pediatric malignant solid tumors christosova,brankov](https://reader035.vdocuments.mx/reader035/viewer/2022062312/556b09abd8b42ae47d8b4936/html5/thumbnails/8.jpg)
Malignant Solid Tumors - 50%
Embrional Tumors - 17% (Neurollastoma - 8%, Nephroblastoma - 7%, Retinollastoma - 1.5%, Hepatoblastoma - 0.5%)
Brain Tumors - 17% (Astrocytoma,Medulloblastoma....)
![Page 9: Pediatric malignant solid tumors christosova,brankov](https://reader035.vdocuments.mx/reader035/viewer/2022062312/556b09abd8b42ae47d8b4936/html5/thumbnails/9.jpg)
Soft Tissue Sarcomas 8% (Rhabdomyosarcoma - 6%...) Bone Tumors - 4% (Sarcoma, Osteogenes, Sarcoma Ewing...) Germ Cell Tumors - 2% Epithelial Tumors - Carcinomas and other very Rare Tumors - 2%
Malignant Solid Tumors - 50%
![Page 10: Pediatric malignant solid tumors christosova,brankov](https://reader035.vdocuments.mx/reader035/viewer/2022062312/556b09abd8b42ae47d8b4936/html5/thumbnails/10.jpg)
Wilms” Tumors(Nephroblastoma)
Epidemiology - 7% of Neoplastic Diseases in Children
Unfavonrable Histology (Focal or Diffuse Anaplasia) - 10%
Favourable Histology (Multicystic and with Fibroadenomatous Structures) - 90%
Gene Mutations - 11p 13 for WT1 and 11p 15 for WT2
Caner Malformation Syndromes
![Page 11: Pediatric malignant solid tumors christosova,brankov](https://reader035.vdocuments.mx/reader035/viewer/2022062312/556b09abd8b42ae47d8b4936/html5/thumbnails/11.jpg)
Incidence
0,0
0,5
1,0
1,5
2,0
2,5
<1 1 2 3 4 5 6 7 8 9 10 11 12 13 14
Girls Boys
Incidence rates per 100,000
Age
![Page 12: Pediatric malignant solid tumors christosova,brankov](https://reader035.vdocuments.mx/reader035/viewer/2022062312/556b09abd8b42ae47d8b4936/html5/thumbnails/12.jpg)
Wilms Tumor:
Histology: mixture of immature cells metanephric, stromal, tubular
Cajaiba MM et al. (2006) Rhabdomyosarcoma, Wilms tumor, and deletion of the patched gene in Gorlin syndrome Nat Clin Pract Oncol 3: 575–580 doi:10.1038/ncponc0608
![Page 13: Pediatric malignant solid tumors christosova,brankov](https://reader035.vdocuments.mx/reader035/viewer/2022062312/556b09abd8b42ae47d8b4936/html5/thumbnails/13.jpg)
Clinical Manifestation
Good Clinical State Haematuria - 25% Abdominal pain - 35% High blood pressure - 35% An abdominal Tumor mass - discovered
accidentally
![Page 14: Pediatric malignant solid tumors christosova,brankov](https://reader035.vdocuments.mx/reader035/viewer/2022062312/556b09abd8b42ae47d8b4936/html5/thumbnails/14.jpg)
Clinical stages
I. Tumor limited to the Kidney, in size - 5 cm. Intact Renal Capsule, Excised Completly.
II. Tumor extends outside the Kidney in size - 10 cm, Excised Completly.
III. Tumor over 10 cm in size. Infiltrated other Organs in Ablomen, without Hematogenous Mts, Complete Excision Impossible.
IV. Tumor with Hematogenous Mts (Lungs - 10% liver - 1% ets.)
V. Bilateral Renal Tumors
![Page 15: Pediatric malignant solid tumors christosova,brankov](https://reader035.vdocuments.mx/reader035/viewer/2022062312/556b09abd8b42ae47d8b4936/html5/thumbnails/15.jpg)
![Page 16: Pediatric malignant solid tumors christosova,brankov](https://reader035.vdocuments.mx/reader035/viewer/2022062312/556b09abd8b42ae47d8b4936/html5/thumbnails/16.jpg)
Laboratory and RadiologicalExaminations
Hb, Plt, WBS, LDH, UrineanalysisCT and Abdominal UltrasoundChest X-
ray Tumor Histology
![Page 17: Pediatric malignant solid tumors christosova,brankov](https://reader035.vdocuments.mx/reader035/viewer/2022062312/556b09abd8b42ae47d8b4936/html5/thumbnails/17.jpg)
![Page 18: Pediatric malignant solid tumors christosova,brankov](https://reader035.vdocuments.mx/reader035/viewer/2022062312/556b09abd8b42ae47d8b4936/html5/thumbnails/18.jpg)
Risk Factors
Low Risk - Cases withl Favourable Histology, in I and II Stages, under 3 Year of Age
High Risk - Cases with Unfavourable Histology, in III, IV and V Stages, over 3 Year of Age
![Page 19: Pediatric malignant solid tumors christosova,brankov](https://reader035.vdocuments.mx/reader035/viewer/2022062312/556b09abd8b42ae47d8b4936/html5/thumbnails/19.jpg)
Treatment
Surgery - Nephrectomy, Lymphadenotomy, Excision when it is possibly of lung or liver Mts. In V stade -partial resection.
Radiotherapy. No RT in I and II stage. In III and IV stage RT in Tumor Region with Dose 20-30 GY. In Mts regions - 15 GY
![Page 20: Pediatric malignant solid tumors christosova,brankov](https://reader035.vdocuments.mx/reader035/viewer/2022062312/556b09abd8b42ae47d8b4936/html5/thumbnails/20.jpg)
Chemotherapy
L. R. Actinomycin D, Vincristine H. R. Act D, Vcr, Farmarubicin, VP16
![Page 21: Pediatric malignant solid tumors christosova,brankov](https://reader035.vdocuments.mx/reader035/viewer/2022062312/556b09abd8b42ae47d8b4936/html5/thumbnails/21.jpg)
Prognosis
Low Risk - 85% survival
High Risk - 40% survival
![Page 22: Pediatric malignant solid tumors christosova,brankov](https://reader035.vdocuments.mx/reader035/viewer/2022062312/556b09abd8b42ae47d8b4936/html5/thumbnails/22.jpg)
Neuroblastoma
Epidemiology - 8% of Neoplastic Diseases in children
Unfavourable Histology (Neuroblastoma) - 90%
Favourable Histology (Ganglioneuroblastoma) - 10%
![Page 23: Pediatric malignant solid tumors christosova,brankov](https://reader035.vdocuments.mx/reader035/viewer/2022062312/556b09abd8b42ae47d8b4936/html5/thumbnails/23.jpg)
Neuroblastoma Localization -
70% Abdomen (1/2 of Cases from suprarenal gl.) 15% Mediastinum, 3% Neck, 8% Paravertebral Region, 4% Other Rare Regions (Olfactory Region, Multiple
Primary Tumors C.N.S ets)
![Page 24: Pediatric malignant solid tumors christosova,brankov](https://reader035.vdocuments.mx/reader035/viewer/2022062312/556b09abd8b42ae47d8b4936/html5/thumbnails/24.jpg)
![Page 25: Pediatric malignant solid tumors christosova,brankov](https://reader035.vdocuments.mx/reader035/viewer/2022062312/556b09abd8b42ae47d8b4936/html5/thumbnails/25.jpg)
Neuroblastoma
“Small blue round cell” tumor Immunohistochemical stains:
neurofilament proteins, synaptophysin, NSE
Electron microscopy: neurosecretory granules, microtubules and filaments
Chromosome 1 deletions or N-myc oncogene amplification
From, Principles and Practice of Pediatric Oncology, Lippincott Williams & Wilkins,
p 903.
![Page 26: Pediatric malignant solid tumors christosova,brankov](https://reader035.vdocuments.mx/reader035/viewer/2022062312/556b09abd8b42ae47d8b4936/html5/thumbnails/26.jpg)
![Page 27: Pediatric malignant solid tumors christosova,brankov](https://reader035.vdocuments.mx/reader035/viewer/2022062312/556b09abd8b42ae47d8b4936/html5/thumbnails/27.jpg)
0
2
4
6
8
10
<1 1 2 3 4 5 6 7 8 9 10 11 12 13 14
Girls Boys
Incidence rates per 100,000
Age
Incidence
![Page 28: Pediatric malignant solid tumors christosova,brankov](https://reader035.vdocuments.mx/reader035/viewer/2022062312/556b09abd8b42ae47d8b4936/html5/thumbnails/28.jpg)
Clinical Manifestation
Poor clinical State Symptoms of Primary Localization Symptoms of Metastatic Localization Paraneoplastic Symptoms
![Page 29: Pediatric malignant solid tumors christosova,brankov](https://reader035.vdocuments.mx/reader035/viewer/2022062312/556b09abd8b42ae47d8b4936/html5/thumbnails/29.jpg)
There are orbital and skull vault metastases, with associated enhancing soft-tissue masses. The skull lesions are extradural masses which deform the underlying brain. The right orbital lesion forms a superior extraconal mass, depressing the right globe.
![Page 30: Pediatric malignant solid tumors christosova,brankov](https://reader035.vdocuments.mx/reader035/viewer/2022062312/556b09abd8b42ae47d8b4936/html5/thumbnails/30.jpg)
bilateral ecchymosis in a child with metastatic neuroblastoma.
![Page 31: Pediatric malignant solid tumors christosova,brankov](https://reader035.vdocuments.mx/reader035/viewer/2022062312/556b09abd8b42ae47d8b4936/html5/thumbnails/31.jpg)
Clinical Stages (Evans et al.)
I Tumor Limited to the Organ or Structure of Origin. Excised Comletely.
II Tumor with Regional Spread, not Crossing the Midline. III Tumor Crossing the Midline, Bilateral Lymph Nodes May by
involved. Complete Excision imposible. IV Tumor with Distant Mts (Bone - 50% of cases, Lymph
Nodes, Organs, Soft Tissues) IV-S Tumor in I and II Cl Stage, with Limited Dissemination to
Liver, Skin and Bone Marrow (without Bones), Infants under 2 Years of Age, especially under 1 Year of Age.
![Page 32: Pediatric malignant solid tumors christosova,brankov](https://reader035.vdocuments.mx/reader035/viewer/2022062312/556b09abd8b42ae47d8b4936/html5/thumbnails/32.jpg)
![Page 33: Pediatric malignant solid tumors christosova,brankov](https://reader035.vdocuments.mx/reader035/viewer/2022062312/556b09abd8b42ae47d8b4936/html5/thumbnails/33.jpg)
Laboratory and Radiological Examinations
Hb, Plt, WBC, LDH, Bone Marrow Aspiration Urinanalysis CT and Abdominal Ultrasound Bone Isotope Scanning, Scanning with 131I-MIBG Chest X-ray Tumor Markers - N-myc, Ferritin, NSE, Cantecholamines’
Metabolites Tumor Histology
![Page 34: Pediatric malignant solid tumors christosova,brankov](https://reader035.vdocuments.mx/reader035/viewer/2022062312/556b09abd8b42ae47d8b4936/html5/thumbnails/34.jpg)
Risk Factors
Low Risk - Cases with Ganglioneuroblastoma, in I, II and IV-S Stages, under 1 Year of age, with Neck and Mediastinum Localisation
High Risk - Cases with Neuroblastoma, in III and IV Stages (Bone Mts), over 2 Years of age, with High Levels of LDH, NSE and Fevritin, with Abdominal and Paravertebral Localisation, with Amplification of N-myc.
![Page 35: Pediatric malignant solid tumors christosova,brankov](https://reader035.vdocuments.mx/reader035/viewer/2022062312/556b09abd8b42ae47d8b4936/html5/thumbnails/35.jpg)
Treatment
Surgery - Survival is better when Radical Excision is done.
Radiotherapy - No RT in I, II and IV-S Stages
In III and IV Stages RT in Tumor and Mts Redions with Dose 15-35 GY.
![Page 36: Pediatric malignant solid tumors christosova,brankov](https://reader035.vdocuments.mx/reader035/viewer/2022062312/556b09abd8b42ae47d8b4936/html5/thumbnails/36.jpg)
Chemotherapy
L. R. - Vcr, Endoxan, Farmarubicin
H. R. - Vcr, Endoxan, VP16, Cisplatin, Carboplatin, Holoxan, Farmarubicin
![Page 37: Pediatric malignant solid tumors christosova,brankov](https://reader035.vdocuments.mx/reader035/viewer/2022062312/556b09abd8b42ae47d8b4936/html5/thumbnails/37.jpg)
Prognosis
Low Risk - 80% survival
High Risk - 35% survival
![Page 38: Pediatric malignant solid tumors christosova,brankov](https://reader035.vdocuments.mx/reader035/viewer/2022062312/556b09abd8b42ae47d8b4936/html5/thumbnails/38.jpg)
Rhabdomyosarcoma
Epidemiology - 5% of NeoplasticDiseases in Children
Histology - Embrional and Botroid - 75%; Alveolar + Pleomorphic - 20%; Undifferentiated - 5%.
Mts - Lungs, Bones, Lymph Nodes, Brain.
![Page 39: Pediatric malignant solid tumors christosova,brankov](https://reader035.vdocuments.mx/reader035/viewer/2022062312/556b09abd8b42ae47d8b4936/html5/thumbnails/39.jpg)
Incidence
0,0
0,3
0,6
0,9
1,2
1,5
<1 1 2 3 4 5 6 7 8 9 10 11 12 13 14
Girls Boys
Incidence rates per 100,000
Age
![Page 40: Pediatric malignant solid tumors christosova,brankov](https://reader035.vdocuments.mx/reader035/viewer/2022062312/556b09abd8b42ae47d8b4936/html5/thumbnails/40.jpg)
Rhabdomyosarcoma Localization
Head and Neck - 40%; Pelvis + Urinary Tract - 25%; Limbs - 20%; Other Rare Localizations - 15%; (Diapharagm
Thorax and Abdominal walls, Viscera and every Region originated from Mesenchyme arising in Striated Muscle.)
![Page 41: Pediatric malignant solid tumors christosova,brankov](https://reader035.vdocuments.mx/reader035/viewer/2022062312/556b09abd8b42ae47d8b4936/html5/thumbnails/41.jpg)
Rhabdomyosarcoma
Clinical Manifestation depends from Primary Localisation.
![Page 42: Pediatric malignant solid tumors christosova,brankov](https://reader035.vdocuments.mx/reader035/viewer/2022062312/556b09abd8b42ae47d8b4936/html5/thumbnails/42.jpg)
Nasopharyngeal Rhabdomyosarcoma
![Page 43: Pediatric malignant solid tumors christosova,brankov](https://reader035.vdocuments.mx/reader035/viewer/2022062312/556b09abd8b42ae47d8b4936/html5/thumbnails/43.jpg)
![Page 44: Pediatric malignant solid tumors christosova,brankov](https://reader035.vdocuments.mx/reader035/viewer/2022062312/556b09abd8b42ae47d8b4936/html5/thumbnails/44.jpg)
Rhabdomyosarcoma
Alveolar– 20% of pediatric cases– Chromosomal translocation:
t(2;13) or t(1;13)
– Gene amplification– Tetraploid DNA
From, Surgical Pathology of the Head and Neck, Lippincott Williams & Wilkins,p 157.
![Page 45: Pediatric malignant solid tumors christosova,brankov](https://reader035.vdocuments.mx/reader035/viewer/2022062312/556b09abd8b42ae47d8b4936/html5/thumbnails/45.jpg)
Rhabdomyosarcoma
Botryoid– 5-10% of pediatric cases– Grape-like tumor masses
Pleomorphic– Rare in children
From, Diagnostic Surgical Pathology of the Head and Neck,
W.B.Saunders, p 554.
![Page 46: Pediatric malignant solid tumors christosova,brankov](https://reader035.vdocuments.mx/reader035/viewer/2022062312/556b09abd8b42ae47d8b4936/html5/thumbnails/46.jpg)
Clinical Stage
I Limited Tumor Excised Comletely. II Grossly Removed Tumor with microscopic
residual disease. III Incomplete Removal or only Biopsy with
Gross Residual Tumor. IV Metastatic Disease at Diagnosis.
![Page 47: Pediatric malignant solid tumors christosova,brankov](https://reader035.vdocuments.mx/reader035/viewer/2022062312/556b09abd8b42ae47d8b4936/html5/thumbnails/47.jpg)
Laboratory and Radiological Examinations
Hb, Plt, WBC, LDH CT and MRI of Primary Tumor Chest X-ray and CT Bone Scan Tumor Histology
![Page 48: Pediatric malignant solid tumors christosova,brankov](https://reader035.vdocuments.mx/reader035/viewer/2022062312/556b09abd8b42ae47d8b4936/html5/thumbnails/48.jpg)
Risk Factors
Low Risk - I and II stages - 70% survival
High Risk - III and IV stages, Parameningial Localization, Alveolar Histology - 30% survival
![Page 49: Pediatric malignant solid tumors christosova,brankov](https://reader035.vdocuments.mx/reader035/viewer/2022062312/556b09abd8b42ae47d8b4936/html5/thumbnails/49.jpg)
Treatment
Surgery Radiotherapy Chemotherapy - Vcr, Holoxan Farmarubicin, VP16, Endoxan Carloplatin, Actinomycin D.
![Page 50: Pediatric malignant solid tumors christosova,brankov](https://reader035.vdocuments.mx/reader035/viewer/2022062312/556b09abd8b42ae47d8b4936/html5/thumbnails/50.jpg)